Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Acute megakaryoblastic leukemia (AMegL)

M7 acute non lymphocytic leukemia (M7-ANLL)

Identity

Note Sometimes presenting as "acute myelofibrosis"
Other namesAML-M7

Clinics and Pathology

Phenotype / cell stem origin This leukemia is thought to derive from the transformation of a multipotent myeloid progenitor cell. In the adult patient multilineage dysplasia is a common finding and in some cases a minority of myeloid blast cells is present.
The blast cells show one or more megakaryocytic markers (i.e. Factor VIII, CD61, CD41, or CD42), they test negative when using the anti-myeloperoxidase monoclonal antibody and never show coordinated expression of lymphoid markers, though isolated CD2 or CD7 positivity can be found on some occasions. The CD34, CD13 and CD33 markers are positive in a substantial fraction of cases, as is the case with the CD36/thrombospondin receptor.
The myeloperoxidase stain is negative by light microscopy, but ultrastructural peroxidase activity with a specific peri-nuclear staining pattern can be detected at the electron microscopy level.
Epidemiology The disease is rare and, due to difficulty in diagnosis, its exact incidence is not known. Reasonably, it may account for approximately 1-2% of all de novo acute myeloid leukemias (AML) in the adult population, but the incidence in the pediatric age group is higher, partly due to an association with Down syndrome.
Clinics The presentation is usually acute, though AMegL may develop after myelodysplastic syndrome or chronic myelogenous leukemia (CML).
In some cases acute myelofibrosis is the presentation picture.
AMegL should be distinguished from AML with megakaryoblastic involvement showing a minority of megakaryoblasts.
In children there is an association with Down syndrome.
Cytology The blast cell morphology varies from case to case. In some patients the blasts are undifferentiated and the diagnosis requires immunophenotyping or electron microscopy studies. Dysmegakaryocytopoiesis is rather frequent. Other patients may show bleb-forming blasts, but this feature is nor specific for megakaryoblasts. Micromegakaryocytes can be frequently seen.
Pathology The bone biopsy almost invariably shows fibrosis, which can be extensive in up to 75% of the cases.
Spleen enlargement is frequently seen in children, less frequently in adults.
Treatment Myeloablative treatment followed, whenever possible, by allogeneic or autologous bone marrow transplant is the treatment of choice
Prognosis In general, the prognosis is severe. 30-to-50 % of the adult patients achieve a complete morphologic remission, but the majority relapse within a few months. Median duration of CR and survival in a study was 10.6 months and 10.4 months, respectively. Some children may fare better, with a 50% 3-year event free survival in AML-M7 post Down Syndrome or with the t(1;22) (see below). Prognosis is dismal in children with other cytogenetic abnormalities.

Cytogenetics

Cytogenetics Morphological a) Adults
There is no cytogenetic anomaly that is specific for AML-M7. The karyotype is abnormal in the vast majority of cases with complex aberrations (i.e. 3 or more clonal aberrations) occurring more frequently than in other AMLs. -5/5q- and/or -7/7q+ are found, as a rule, in virtually all cases with complex karyotype, which globally account for 70-80% of abnormal cases.
3q21 or q26 aberrations are found in 20-30% of the cases; the t(9;22) is another recurrent chromosome aberrations in de novo AML-M7.
Trisomy 19 and 21 may occur in de novo as well as in secondary AML-M7. They are the most frequently occurring chromosome gains and they may be associated with any of the cytogenetic group listed above.

b) Children
The t(1;22)(p13;q13) is specifically associated with children AML-M7, being found in approximately half of the cases. The remaining patients may show +21 (irrespective of the association with Down syndrome), +19, +8. The karyotype may be normal in approximately 10% of the cases.

Cytogenetics Molecular Partial trisomy 19, involving the q13 band, can be shown to occur at a 20-30% incidence by comparative genomic hybridization
The t(1;22)(p13;q13) fuses the OTT(RBM15) gene on 1p13 to the MAL(MLK1) gene on chromosome 22, leading to the OTT-MAL fusion gene on the derivative 22

Genes involved and Proteins

Gene Name OTT (one twenty-two) or RBM15(Rna-binding motif protein 15)
Location 1p13
Gene Name MAL (Megakaryocytic acute leukemia) or MLK1 (megakaryoblastic leukemia-1)
Location 22q13

Result of the chromosomal anomaly

Hybrid gene
Note The fusion gene OTT-MAL is on the der(22) chromosome and contains almost all of the sequences of each gene.
  

Other genes implicated (Data extracted from papers in the Atlas)

Genes MLLT10 CSF1R ERG ETV6 GFI1B GLIS2 JAK3

Translocations implicated (Data extracted from papers in the Atlas)

Bibliography

Megakaryoblastic acute leukemia: identification by the ultrastructural demonstration of platelet peroxidase.
Breton-Gorius J, Reyes F, Duhamel G, Najman A, Gorin NC
Blood. 1978 ; 51 (1) : 45-60.
PMID 201318
 
Megakaryoblastic leukemia and Down's syndrome: a review.
Zipursky A, Peeters M, Poon A
Pediatric hematology and oncology. 1987 ; 4 (3) : 211-230.
PMID 2978961
 
Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics.
San Miguel JF, Gonzalez M, Caˆ±izo MC, Ojeda E, Orfao A, Caballero MD, Moro MJ, Fisac P, Lopez Borrasca A
Blood. 1988 ; 72 (2) : 402-407.
PMID 3165292
 
Multipotent stem cell involvement in megakaryoblastic leukemia: cytologic and cytogenetic evidence in 15 patients.
Cuneo A, Mecucci C, Kerim S, Vandenberghe E, Dal Cin P, Van Orshoven A, Rodhain J, Bosly A, Michaux JL, Martiat P
Blood. 1989 ; 74 (5) : 1781-1790.
PMID 2790202
 
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.
Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH, Dewald G, Cassileth PA, Oken MM, Rowe JM
Blood. 2000 ; 96 (7) : 2405-2411.
PMID 11001891
 
Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization.
Alvarez S, MacGrogan D, Calasanz MJ, Nimer SD, Jhanwar SC
Genes, chromosomes & cancer. 2001 ; 32 (3) : 285-293.
PMID 11579469
 
Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia.
Ma Z, Morris SW, Valentine V, Li M, Herbrick JA, Cui X, Bouman D, Li Y, Mehta PK, Nizetic D, Kaneko Y, Chan GC, Chan LC, Squire J, Scherer SW, Hitzler JK
Nature genetics. 2001 ; 28 (3) : 220-221.
PMID 11431691
 
Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia.
Mercher T, Coniat MB, Monni R, Mauchauffe M, Nguyen Khac F, Gressin L, Mugneret F, Leblanc T, Dastugue N, Berger R, Bernard OA
Proceedings of the National Academy of Sciences of the United States of America. 2001 ; 98 (10) : 5776-5779.
PMID 11344311
 
Chromosome 19 abnormalities are commonly seen in AML, M7.
Nimer SD, MacGrogan D, Jhanwar S, Alvarez S
Blood. 2002 ; 100 (10) : 3838-3839.
PMID 12411327
 
Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Franˆßais de Cytogˆ©nˆ©tique Hˆ©matologique (GFCH).
Dastugue N, Lafage-Pochitaloff M, Pagˆ®s MP, Radford I, Bastard C, Talmant P, Mozziconacci MJ, Lˆ©onard C, Bilhou-Nabˆ©ra C, Cabrol C, Capodano AM, Cornillet-Lefebvre P, Lessard M, Mugneret F, Pˆ©rot C, Taviaux S, Fenneteaux O, Duchayne E, Groupe Franˆßais d'Hematologie Cellulaire, Berger R
Blood. 2002 ; 100 (2) : 618-626.
PMID 12091356
 
Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Franˆßais de Cytogˆ©nˆ©tique Hˆ©matologique (GFCH).
Dastugue N, Lafage-Pochitaloff M, Pagˆ®s MP, Radford I, Bastard C, Talmant P, Mozziconacci MJ, Lˆ©onard C, Bilhou-Nabˆ©ra C, Cabrol C, Capodano AM, Cornillet-Lefebvre P, Lessard M, Mugneret F, Pˆ©rot C, Taviaux S, Fenneteaux O, Duchayne E, Groupe Franˆßais d'Hematologie Cellulaire, Berger R
Blood. 2002 ; 100 (2) : 618-626.
PMID 12091356
 
Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Franˆßais d'Hˆ©matologie Cellulaire (GFHC).
Duchayne E, Fenneteau O, Pages MP, Sainty D, Arnoulet C, Dastugue N, Garand R, Groupe Franˆßais d'Hˆ©matologie Cellulaire, Groupe Franˆßais de Cytogˆ©nˆ©tique Hˆ©matologique, Flandrin G
Leukemia & lymphoma. 2003 ; 44 (1) : 49-58.
PMID 12691142
 
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed

Contributor(s)

Written11-2003Antonio Cuneo, Francesco Cavazzini, Gianluigi Castoldi

Citation

This paper should be referenced as such :
Cuneo, A ; Cavazzini, F ; Castoldi, GL
Acute megakaryoblastic leukemia (AMegL) - M7 acute non lymphocytic leukemia (M7-ANLL)
Atlas Genet Cytogenet Oncol Haematol. 2004;8(1):29-30.
Free online version   Free pdf version   [Bibliographic record ]
URL : http://AtlasGeneticsOncology.org/Anomalies/M7ANLLID1100.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Sep 5 13:08:52 CEST 2014


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.